Oncolytics Biotech Investor Presentation 2020

Clinical-stage biotechnology company developing pelareorep, a first-in-class systemically administered immuno-oncology agent for solid tumors and hematologic malignancies. The company is evaluating pelareorep's potential synergies with immune checkpoint inhibitors in ongoing clinical trials.